Blood-Brain Barrier– tag –
-
Oligonucleotide Drug Delivery Shifts Beyond Liver-Targeting to Tissue-Specific Approaches for Muscle and CNS
GlobeNewswire Unknown Overview Oligonucleotide drug delivery is evolving significantly, moving from traditional liver-targeted strategies to tissue-specific approaches for extrahepatic organs like muscle and the central nervous system (C... -
University of Virginia Pioneers Focused Ultrasound for Temporary Blood-Brain Barrier Opening, Redefining Drug Size Impact on Delivery
Physics World USA Overview Researchers at the University of Virginia have developed a pioneering method using focused ultrasound (FUS) to temporarily open the blood-brain barrier (BBB) for drug delivery to the brain. Utilizing MRI physic... -
Caltech Unveils ‘BrainCAB’ Molecular Shuttle for Enhanced Blood-Brain Barrier Drug Delivery Targeting Carbonic Anhydrase IV
Caltech News USA Overview Caltech researchers have developed 'BrainCAB,' a novel molecular shuttle that efficiently crosses the blood-brain barrier (BBB) to deliver drugs to the brain. This technology utilizes a small molecule shuttle th... -
Molecular Glue Degraders Expand Druggable Proteome in Cancer Research: Simple Structure Boosts CNS Delivery Potential
Facebook USA Overview Molecular glue degraders, small molecules that stabilize interactions between otherwise non-interacting proteins, are expanding the 'druggable' proteome in cancer research through targeted protein degradation. Unlik... -
New Blood-Brain Barrier Penetration Strategies: Peptides and ‘Trojan Horse’ Approaches Revolutionize Brain Drug Delivery
Facebook USA Overview The blood-brain barrier (BBB) blocks approximately 95% of drugs, severely impeding treatment for brain disorders. Researchers are developing novel techniques to bypass this barrier, including 'Trojan horse' approach... -
Unicorn Bioscience Report: Exosome Therapy Market Valued at $58.1 Billion Despite No FDA Approvals, 240 Clinical Trials Underway
Unicorn Bioscience Unknown Overview This article provides an overview of a market research report published by Unicorn Bioscience. As of 2026, the global therapeutic exosome market is valued at $58.1 billion, a paradoxical valuation give... -
Alector Advances ‘Brain Carrier’ Platform: Optimizing Brain Drug Delivery via Transferrin Receptor Targeting with Enhanced Safety
Alector USA Overview Alector recently announced significant progress with its proprietary Alector Brain Carrier (ABC) blood-brain barrier (BBB) platform, designed to substantially enhance the delivery of therapeutic agents to the brain. ... -
Nanomedicine Conquers Glioblastoma’s Blood-Brain Barrier: Revolutionizing Treatment via Targeted Delivery, Stimuli-Responsiveness, and AI
Drug Target Review UK Overview Nanomedicine is emerging as a critical solution to overcome the formidable blood-brain barrier (BBB) in treating glioblastoma (GBM), the most aggressive brain tumor. Researchers are developing advanced nano... -
Nanoparticle Breakthroughs: Piercing the Blood-Brain Barrier to Revolutionize CNS Disease Treatment, Including Glioblastoma
MDPI Switzerland Overview Nanoparticle-based drug delivery systems are emerging as a pivotal solution for overcoming the blood-brain barrier (BBB), a critical challenge in treating central nervous system (CNS) diseases. A recent review h... -
Exosome Therapeutics Advancing in Neurodegenerative and Oncology Fields, Eyeing Blood-Brain Barrier Penetration
BioInformant Global Overview Exosome therapeutics are showing significant promise in 2026, particularly for neurodegenerative diseases due to their unique ability to cross the blood-brain barrier, with clinical development also progressi...
